| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/16/2003 | WO2003004022A1 Aryl (or heteroaryl) azolylcarbynol derivatives for the treatment of urinary incontinence |
| 01/16/2003 | WO2003004020A1 Heteroaryl carboxylic acid amides, the production thereof and the use of the same as inhibitors of the microsomal triglyceride transfer protein (mtp) |
| 01/16/2003 | WO2003004019A1 Use of heterocyclic and benzoheterocyclic polyamides structurally related to the natural antibiotic distamycin a for the treatment of beta-thalassaemia |
| 01/16/2003 | WO2003004018A1 Cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives as gaba-a receptor ligands |
| 01/16/2003 | WO2003004017A1 Synergistic compositions of n-acylhomoserine lactones and 4-quinolones |
| 01/16/2003 | WO2003004016A1 Use of substituted gamma-lactone compounds as medicaments |
| 01/16/2003 | WO2003004015A1 Oil-in-water emulsions comprising a benzodiazepine drug |
| 01/16/2003 | WO2003004014A1 Organometallic anti-tumour agent |
| 01/16/2003 | WO2003004013A1 Wound treatment agent |
| 01/16/2003 | WO2003004012A1 Calcium l-threonate for preventing or treating cartilage related diseases |
| 01/16/2003 | WO2003004011A1 Calcium l-threonate for preventing or treating bone facture |
| 01/16/2003 | WO2003004010A1 Carbonylamino derivatives useful for obtaining immune regulation |
| 01/16/2003 | WO2003004009A1 Pharmaceutical composition |
| 01/16/2003 | WO2003004008A2 Pharmaceutical composition for prophylaxis and treatment of calcium metabolism disorders comprising clodronate in combination with glyceryl palmitostearate |
| 01/16/2003 | WO2003004007A2 Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd) |
| 01/16/2003 | WO2003004006A2 Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
| 01/16/2003 | WO2003004005A1 Optimised formulation of tobramycin for aerosolization |
| 01/16/2003 | WO2003004003A1 Soft capsules |
| 01/16/2003 | WO2003004002A1 Sublingual administration of dihydroergotamine for the treatment of migraine |
| 01/16/2003 | WO2003004000A2 Topical composition for treating pain |
| 01/16/2003 | WO2003003999A2 Delivery of a bioactive material |
| 01/16/2003 | WO2003003987A2 Solid phase synthesis of arylretinamides |
| 01/16/2003 | WO2003003981A2 Compositions for improving mental performance |
| 01/16/2003 | WO2003003978A2 An oral formulation of methylglyoxal and its imino acid conjugates for human use |
| 01/16/2003 | WO2003003977A2 Compositions and methods for the treatment of body weight disorders, including obesity |
| 01/16/2003 | WO2003003976A2 Compositions for removing human cerumen |
| 01/16/2003 | WO2003003975A2 Detection and therapy of vulnerable plaque with photodynamic compounds |
| 01/16/2003 | WO2003003973A2 Composition of a bioflavonoid complex siblarex for bioactive additives for medicinal and chemicopharmaceutical products, method for producing said bioflavonoid complex for bioactive additives for medicinal and chemicopharmaceutical products |
| 01/16/2003 | WO2003003972A2 Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof |
| 01/16/2003 | WO2003003971A2 Use of antidiabetics for making a medicine with cicatrizing effect |
| 01/16/2003 | WO2003003833A1 Antiviral composition and treatment method |
| 01/16/2003 | WO2003003828A1 Material for improving living environment, and building material, laying material and spraying agent using the same |
| 01/16/2003 | WO2003003806A2 Dye-azide compounds for dual phototherapy |
| 01/16/2003 | WO2002096415A3 Use of azetidinone substituted derivatives in the treatment of alzheimer's disease |
| 01/16/2003 | WO2002096394A3 Pharmaceutical composition containing stool softener such as polaxamer and enteric coated particles of bisacodyl |
| 01/16/2003 | WO2002094246A3 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route |
| 01/16/2003 | WO2002094244A3 Delivery of benzodiazepines through an inhalation route |
| 01/16/2003 | WO2002085857A3 Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| 01/16/2003 | WO2002078676A3 Enteric ketoacid salts and amino acids |
| 01/16/2003 | WO2002077023A3 A new essential downstream component of the wingless signalling pathway |
| 01/16/2003 | WO2002076930A3 Substituted diarylureas as stimulators for fas-mediated apoptosis |
| 01/16/2003 | WO2002072527A3 1-butyric acid derivatives such as carbomethoxypropionyl cyanide or leflunomide derivatives, and the therapeutic use thereof |
| 01/16/2003 | WO2002067968A3 14-3-3 binding molecules as sensitizers for anticancer therapies |
| 01/16/2003 | WO2002067893A3 Pharmaceutical formulation comprising bicalutamide |
| 01/16/2003 | WO2002062327A3 Method of treating neurological disorders using acetone derivatives |
| 01/16/2003 | WO2002051837A3 Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands |
| 01/16/2003 | WO2002051399A3 Divalproex sodium dosage forms and a process for their production |
| 01/16/2003 | WO2002051389A3 Aerogel powder comprising therapeutic agents |
| 01/16/2003 | WO2002050062A3 Benzimidazole and pyridylimidazole derivatives as ligands for gaba receptors |
| 01/16/2003 | WO2002050034A3 Tetracyclic carbazole derivates and their use as spla2 inhibitors |
| 01/16/2003 | WO2002049613A3 Method for enhancing integrity of epithelium using retinoic acid |
| 01/16/2003 | WO2002045658A3 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof |
| 01/16/2003 | WO2002042445A3 Differentiated cells suitable for human therapy |
| 01/16/2003 | WO2002040540A3 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| 01/16/2003 | WO2002040016A3 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 01/16/2003 | WO2002038185A3 Injectable sustained release delivery system with loperamide |
| 01/16/2003 | WO2002036107A3 Treatment of motor fluctuations with 5-hydroxytryptamine 1a receptor activity enhancing coumpounds |
| 01/16/2003 | WO2002034247A3 Anticancer agents based on regulation of protein prenylation |
| 01/16/2003 | WO2002033044A3 Methods of high-throughput screening for internalizing antibodies |
| 01/16/2003 | WO2002032425A3 Stable oral formulation containing benzimidazole derivative |
| 01/16/2003 | WO2002031109A3 Intracellular delivery of biological effectors by novel transporter peptide sequences |
| 01/16/2003 | WO2002028832A3 Diindolylmethane and c-substituted diindolylmethane compositions and methods for the treatment of multiple cancers |
| 01/16/2003 | WO2002028388A3 Use of mek1 inhibitors as protective agents against damage due to ischemia |
| 01/16/2003 | WO2002026216A8 Pharmaceutical oxan preparation |
| 01/16/2003 | WO2002022171A3 Pharmaceutical composition having specific water activity |
| 01/16/2003 | WO2002022107A3 Pharmaceutical composition having modified carrier |
| 01/16/2003 | WO2002012196A3 Lactam compounds and their use as inhibitors of serine proteases and method |
| 01/16/2003 | WO2002011715A3 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 01/16/2003 | WO2002005818A3 Novel method of use of multidrug resistance modulators |
| 01/16/2003 | WO2002004021A9 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
| 01/16/2003 | WO2002002772A3 Human extracellular matrix (ecm)-related tumor marker |
| 01/16/2003 | WO2002002094A3 Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy |
| 01/16/2003 | WO2002000209A3 Gabapentin analogues for sleep disorders |
| 01/16/2003 | WO2001095874A3 Highly efficient delivery of a large therapeutic mass aerosol |
| 01/16/2003 | WO2001091739A3 Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
| 01/16/2003 | WO2001090156A3 Card domain containing polypeptides, encoding nucleic acids, and methods of use |
| 01/16/2003 | WO2001090136A3 Triterpenoid derivatives |
| 01/16/2003 | WO2001074898A3 Charged compounds comprising a nucleic acid binding moiety and uses therefor |
| 01/16/2003 | WO2001062705A3 Aminoalcohol derivatives |
| 01/16/2003 | WO2001060778A3 Aspirin-triggered lipid mediators |
| 01/16/2003 | WO2001060315A3 Method for the treatment or prevention of flavivirus infections using nucleoside analogues |
| 01/16/2003 | WO2001058954A9 Trade molecules and uses related thereto |
| 01/16/2003 | WO2001052868A9 Combinations for treating neoplasms |
| 01/16/2003 | WO2001051049A9 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders |
| 01/16/2003 | WO1995032984A8 New lipid esters of nucleoside monophosphates and their use as immunosuppressive drugs |
| 01/16/2003 | US20030013898 Pericyte protective agent |
| 01/16/2003 | US20030013890 Such as 2-(1-chloro-cycloprop-1-yl)-1-(2-chloro-phenyl)-3-(4,5-dihydro-1,2,4 -triazole-5-thiono-1-yl)-propan-2-ol; microbiocides; fungicides |
| 01/16/2003 | US20030013889 Process for the preparation of taxane derivatives |
| 01/16/2003 | US20030013886 Such as (E)-1-(2-Pyridyl)-2-styryl-1H-benzimidazole; antiinflammatory and analgesic agents; prostaglandin inhibitors |
| 01/16/2003 | US20030013875 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| 01/16/2003 | US20030013874 Non-opioid analgesics for chronic and acute pain; 1-[1-(p-phenylbenzyl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-dione; modulation of the opioid and ORL I receptors; agonist or antagonist activity at the CNS mu, delta and kappa receptors greater than morphine |
| 01/16/2003 | US20030013861 E-isomeric fullerene derivatives |
| 01/16/2003 | US20030013860 Azalide isomers, water, and acids |
| 01/16/2003 | US20030013847 Pyruvate derivatives |
| 01/16/2003 | US20030013846 Cytoprotective agents |
| 01/16/2003 | US20030013773 Hop-based udder and teat dips and washes |
| 01/16/2003 | US20030013772 Composition, synthesis and therapeutic applications of polyamines |
| 01/16/2003 | US20030013771 Concurrent administering with drug; side effect reduction; central nervous system disorders |
| 01/16/2003 | US20030013770 Aminobenzophenones as inhibitors of il 1b and tnf |
| 01/16/2003 | US20030013767 Method of treating weight loss using creatine |